US4351831A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process and composition for treating disorders by administering isoxsurpine and choline
Assignee: Massachusetts Institute of Technology
•
Filing: 1981-01-30
•
Granted: 1982-09-28
•
Expires: 2001-01-30
Abstract
Abstract Choline or a natural or synthetic compound that dissociates to form choline is administered to a patient concomitantly with a drug in order to potentiate the effect of the drug by increasing acetylcholine levels in the brain or other tissues, and/or to suppress, or block the development of, unwanted side effects of the drug, by increasing acetylcholine levels in the brain or other tissues.
Inventors
- 👤 John H. Growdon
- 👤 Richard J. Wurtman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 13:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/683; A61K31/685; A61K31/13; A61K31/14; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/435; A61K31/44; A61K31/445; A61K31/495; A61K31/54; A61K31/55; A61K33/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
97 words
The process of reducing or eliminating undesirable side effects of a drug administered to a human which side effects result from inadequate release of brain acetylcholine, said drug being selected from the group consisting of isoxsuprine and dihydroergotamine, which comprises administering concomitantly with the drug an amount of a compound effective to release adequate amounts of brain acetylcholine and to raise the blood concentration of choline in the human to between about 10 and about 50 n moles/ml selected from the group consisting of choline, a salt of choline, lysolecithin and acyglycerophosphocholine, glycerophosphatidyl choline and mixtures thereof.
Claim 2
Dependent Claim
97 words
The process of reducing or eliminating undesirable side effects of a drug administered to a human which side effects result from inadequate release of brain acetylcholine, said drug being selected from the group consisting of isoxsuprine and dihydroergotamine, which comprises administering concomitantly with the drug an amount of a compound effective to release adequate amounts of brain acetylcholine and to raise the blood concentration of choline in the human to between about 10 and about 50 n moles/ml selected from the group consisting of choline, a salt of choline, lysolecithin and acyglycerophosphocholine, glycerophosphatidyl choline and mixtures thereof.
Claim 3
Dependent Claim
19 words
The process of claim 1 wherein the drug and the compound are administered together as a capsule or tablet.
Claim 4
Dependent Claim
17 words
The process of claim 1 wherein the drug and the compound are administered together in a liquid.
Claim 5
Dependent Claim
11 words
The process of claim 1 wherein the compound is an acyglycerophosphocholine.
Claim 6
Dependent Claim
10 words
The process of claim 4 wherein the acyglycerophosphocholine is lecithin.
Claim 7
Dependent Claim
11 words
The process of claim 1 wherein the compound is choline chloride.
Claim 8
Dependent Claim
115 words
A composition of matter comprising (a) a drug which, when administered to a human causes side effects associated with inadequate release of brain acetylcholine, said drug being selected from the group consisting of isoxsuprine and a dihydroergotamine and (b) an amount of a compound effective to release adequate amounts of brain acetylcholine and to increase the choline level of a patient to between about 10 and 50 n moles/ml selected from the group consisting of choline, a salt of choline, lysolecithin, an acyglycero phosphocholine having the formula: ##STR2## wherein FA 1 and FA 2 can be the same or different and are fatty acid residues having from 6-26 carbon atoms, glycerophosphatidyl choline and mixtures thereof.
Claim 9
Dependent Claim
115 words
A composition of matter comprising (a) a drug which, when administered to a human causes side effects associated with inadequate release of brain acetylcholine, said drug being selected from the group consisting of isoxsuprine and a dihydroergotamine and (b) an amount of a compound effective to release adequate amounts of brain acetylcholine and to increase the choline level of a patient to between about 10 and 50 n moles/ml selected from the group consisting of choline, a salt of choline, lysolecithin, an acyglycero phosphocholine having the formula: ##STR2## wherein FA 1 and FA 2 can be the same or different and are fatty acid residues having from 6-26 carbon atoms, glycerophosphatidyl choline and mixtures thereof.
Claim 10
Dependent Claim
11 words
The composition of claim 7 wherein the compound is an acyglycerophosphocoline.
Claim 11
Dependent Claim
10 words
The composition of claim 8 wherein the acyglycerophosphocholine is lecithin.
Claim 12
Dependent Claim
14 words
The composition of claims 7, 8 or 9 wherein the compound is choline chloride.
Claim 13
Dependent Claim
17 words
The composition of any one of claims 7, 8, 9 or 10 wherein the drug is isoxsurpine.
Claim 14
Dependent Claim
17 words
The composition of any one of claims 7, 8, 9 or 10 wherein the drug is dihydroergotamine.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-09-27 | 1986-03-29 | 1986-09-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-09-27 | 1990-03-29 | 1990-09-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-09-27 | 1994-03-29 | 1994-09-28 | $7700.00 | Window Closed / Lapsed |